Videos

Video of Dave Dixon explaining the impact of first FDA approval of a generic DOAC.

FDA clears first generic versions of rivaroxaban—what it means for patient care

Dave Dixon, PharmD, explored the short- and long-term impact of these approvals, noting that they could help reduce costs down the line.

David A. Rosman, MD, MBA, deputy chief, radiology enterprise service, Mass General Brigham, explains details of a recent AJR article that showed imaging outside of hospitals could potentially save billions.

Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Jason Poff, MD, director of innovation deployment for artificial intelligence (AI) at RadPartners, explains the five-step process he uses to evaluate medical imaging AI.

5 steps for evaluating radiology AI applications

Jason Poff, MD, director of innovation deployment for artificial intelligence at Radiology Partners, explains the process he uses to evaluate medical imaging AI. 
 

ACC Vice President Christopher Kramer, MD, FACC, offers an update on the creation of a new cardiovascular board.

Final decision on the creation of a new cardiovascular board expected soon

U.S. cardiology groups have worked together to propose the creation of a new American Board of Cardiovascular Medicine for certifying cardiologists. Now, after many months of waiting, a final decision is expected by the end of February. 

ACC President Cathie Biga explains the American College of Cardiology advocacy efforts in Washington D.C. in 2025.

ACC president details key advocacy efforts in cardiology

American College of Cardiology President Cathie Biga, MSN, says Medicare payment reform remains a top priority going forward. Site-neutral payments and improved access to PAD screening are two other issues close to the ACC's heart. 

Nina Kottler, MD, Radiology Partners, offers overview of the U.S. AI regulatory landscape as government and radiologists work on ways to ensure artificial intelligence is not bias and works properly.

Overview of the regulatory landscape of AI in radiology

Nina Kottler, MD, associate CMO for clinical AI at Radiology Partners, explains the movement toward greater regulation of artificial intelligence and the need to test for bias. 

Medicare money payment

Medicare Advantage faces criticism for administrative burdens, pushing doctors to opt out

Medical Group Management Association (MGMA) Senior Vice of Government Affairs, Anders Gilberg, explains the frustration surrounding the Medicare Advantage program.

 

Melissa Davis, MD, MBA, Yale University, explains her research into private equity market penetration in radiology.

Concerns about private equity's growing influence in radiology

Melissa Davis, MD, vice chair of medical informatics and associate professor at Yale University’s Department of Radiology and Biomedical Imaging, shares her findings from research on private equity market penetration.

 

Around the web

If the Trump administration continues taking a laissez-faire stance toward AI—including AI used in healthcare—why not let the states go it alone on regulating the technology? 

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.